Activity of decitabine combined with all- trans retinoic acid in oligoblastic acute myeloid leukemia: results from a randomized 2x2 phase II trial (DECIDER)

Christoph Rummelt; Olga Grishina; Claudia Schmoor; Martina Crysandt; Michael Heuser; Katharina S Götze; Richard F Schlenk; Konstanze Döhner; Helmut R Salih; Gerhard Heil; Carsten Müller-Tidow; Wolfram Brugger; Andrea Kündgen; Maike De Wit; Aristoteles Giagounidis; Sebastian Scholl; Andreas Neubauer; Jürgen Krauter; Gesine Bug; Haifa Kathrin Al-Ali; Ralph Wäsch; Heiko Becker; Annette M May; Justus Duyster; Björn Hackanson; Arnold Ganser; Hartmut Döhner; Michael Lübbert

doi:10.3324/haematol.2022.282258

Activity of decitabine combined with all- trans retinoic acid in oligoblastic acute myeloid leukemia: results from a randomized 2x2 phase II trial (DECIDER)

Haematologica. 2023 Aug 1;108(8):2244-2248. doi: 10.3324/haematol.2022.282258.

Authors

Christoph Rummelt¹, Olga Grishina², Claudia Schmoor², Martina Crysandt³, Michael Heuser⁴, Katharina S Götze⁵, Richard F Schlenk⁶, Konstanze Döhner⁷, Helmut R Salih⁸, Gerhard Heil⁹, Carsten Müller-Tidow¹⁰, Wolfram Brugger¹¹, Andrea Kündgen¹², Maike De Wit¹³, Aristoteles Giagounidis¹⁴, Sebastian Scholl¹⁵, Andreas Neubauer¹⁶, Jürgen Krauter¹⁷, Gesine Bug¹⁸, Haifa Kathrin Al-Ali¹⁹, Ralph Wäsch¹, Heiko Becker²⁰, Annette M May²¹, Justus Duyster²⁰, Björn Hackanson²², Arnold Ganser⁴, Hartmut Döhner²³, Michael Lübbert²⁴

Affiliations

¹ Department of Hematology, Oncology and Stem Cell Transplantation, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg.
² Clinical Trials Unit, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg.
³ Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen University, Aachen.
⁴ Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover.
⁵ Department of Medicine III, Technical University of Munich, Munich, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner Site Munich, München.
⁶ Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany; National Center of Tumor Diseases, NCT-Trial Center, German Cancer Research Center, Heidelberg.
⁷ Department of Internal Medicine III, University Hospital of Ulm, Ulm.
⁸ Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner Site Tübingen, Tuebingen.
⁹ Department of Hematology/Oncology, Klinikum Luedenscheid, Luedenscheid.
¹⁰ Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner Site Heidelberg, Heidelberg, Germany; Department of Medicine A, University Hospital of Münster, Münster.
¹¹ Department of Hematology, Hospital Villingen-Schwenningen, Villingen-Schwenningen.
¹² Department of Hematology, Oncology and Clinical Immunology, Heinrich- Heine-University, Faculty of Medicine, Düsseldorf, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner Site Düsseldorf, Düsseldorf.
¹³ Department of Hematology and Oncology, Vivantes Klinikum Neukölln, Berlin.
¹⁴ Clinic for Oncology, Hematology and Palliative Medicine, Marien-Hospital Düsseldorf, Düsseldorf.
¹⁵ Department of Hematology and Oncology, Universitätsklinikum Jena, Klinik für Innere Medizin II, Jena.
¹⁶ Department of Hematology and Oncology, University Clinic Gießen/Marburg, Marburg.
¹⁷ Department of Internal Medicine III, Städtisches Klinikum Braunschweig, Braunschweig.
¹⁸ Department of Medicine II, Hematology and Oncology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner Site Frankfurt, Frankfurt.
¹⁹ Krukenberg Cancer Center, University Hospital Halle, Halle.
²⁰ Department of Hematology, Oncology and Stem Cell Transplantation, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner Site Freiburg, Freiburg.
²¹ Institute for Surgical Pathology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg.
²² Department of Hematology, Oncology and Stem Cell Transplantation, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany; Department of Hematology/Oncology, Universitätsklinikum Augsburg, Augsburg.
²³ Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg.
²⁴ Department of Hematology, Oncology and Stem Cell Transplantation, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg. [email protected].

No abstract available

Publication types

Clinical Trial, Phase II
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Azacitidine / therapeutic use
Decitabine / therapeutic use
Humans
Leukemia, Myeloid, Acute* / drug therapy
Tretinoin / therapeutic use

Substances

Decitabine
Tretinoin
Azacitidine

Grants and funding

Funding: The study was supported by the German Federal Ministry of Education and Research (BMBF, Clinical Trials Program Grant No 01KG0913). Decitabine was provided by Janssen-Cilag, valproic acid was provided by TEVA. The study was further supported by the German Research Foundation (DFG consortia FOR2674, CRC992) for translational studies conducted by ML (A05, C04), HB (A05), HD (A02).